For millions of adults using GLP-1 receptor agonists or tirzepatide to manage obesity and type 2 diabetes, stopping treatment may carry risks that go well beyond simply regaining lost weight. This emerging concern reframes these medications not as short-term interventions but as therapies whose interruption may actively destabilize cardiometabolic health — a distinction with profound implications for how clinicians and patients approach treatment planning.

Real-world persistence data from the past two years reveal that a substantial proportion of patients discontinue GLP-1 receptor agonists or tirzepatide within the first twelve months of therapy. Primary drivers include gastrointestinal side effects, insufficient weight loss response, prohibitive out-of-pocket costs, and anxiety around rare adverse events. Upon discontinuation, patients commonly experience not only weight regain but deterioration across multiple cardiometabolic markers. Crucially, cyclical patterns of starting, stopping, and restarting these agents appear to generate fluctuations in both body weight and HbA1c — both established independent risk factors for cardiovascular and microvascular disease. The absence of anti-atherosclerotic and plaque-stabilizing activity in incretin-based drugs may compound acute cardiovascular vulnerability in the period immediately following cessation.

This analysis lands at a critical moment in metabolic pharmacology. The "weight cycling" literature has long associated repeated weight loss and regain with adverse cardiovascular outcomes, and this review extends that concern specifically to pharmacologically-driven cycles. The finding distinguishes GLP-1 agents from antihypertensives or statins, where drug holidays carry different risk profiles. A meaningful limitation here is the acknowledged scarcity of prospective data quantifying discontinuation-related event incidence — most evidence remains observational or extrapolated from trial populations that differ from real-world users. For health-conscious adults considering these medications, the practical implication is clear: access barriers, tolerability management, and long-term adherence planning deserve as much clinical attention as initiating therapy. This paper is likely to be viewed as paradigm-shifting in how discontinuation risk is counseled at the point of prescription.